Ultragenyx Pharmaceutical annual free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ultragenyx Pharmaceutical Free Cash Flow (FCF) History (RARE)
Ultragenyx Pharmaceutical reported −$472.0M in free cash flow for fiscal 2025, a decrease of $51.0M from the previous fiscal year, with a free cash flow margin of −70.13%.
View full Ultragenyx Pharmaceutical company overviewUltragenyx Pharmaceutical free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$472.0M | −$51.0M | — | −70.13% |
| 2024 | 2024-12-31 | −$421.0M | $98.0M | — | −75.18% |
| 2023 | 2023-12-31 | −$519.0M | −$22.4M | — | −119.59% |
| 2022 | 2022-12-31 | −$496.6M | −$84.8M | — | −136.68% |
| 2021 | 2021-12-31 | −$411.8M | −$235.7M | — | −117.18% |
| 2020 | 2020-12-31 | −$176.1M | $194.1M | — | −64.98% |
| 2019 | 2019-12-31 | −$370.2M | −$75.6M | — | −356.96% |
| 2018 | 2018-12-31 | −$294.6M | −$38.0M | — | −572.18% |
| 2017 | 2017-12-31 | −$256.6M | −$85.5M | — | −9825.27% |
| 2016 | 2016-12-31 | −$171.2M | −$60.2M | — | −128693.98% |
| 2015 | 2015-12-31 | −$110.9M | −$64.1M | — | — |
| 2014 | 2014-12-31 | −$46.8M | −$15.2M | — | — |
| 2013 | 2013-12-31 | −$31.6M | −$18.0M | — | — |
| 2012 | 2012-12-31 | −$13.6M | — | — | — |
Ultragenyx Pharmaceutical quarterly free cash flow
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$98.0M | $14.0M | — | −45.79% |
| Q1 2026 | 2026-03-31 | −$198.0M | −$31.0M | — | −145.59% |
| Q4 2025 | 2025-12-31 | −$100.8M | −$21.3M | — | −48.66% |
| Q3 2025 | 2025-09-30 | −$92.2M | −$23.6M | — | −57.67% |
| Q2 2025 | 2025-06-30 | −$112.0M | −$33.0M | — | −67.07% |
| Q1 2025 | 2025-03-31 | −$167.0M | $26.9M | — | −120.14% |
| Q4 2024 | 2024-12-31 | −$79.5M | $6.0M | — | −48.27% |
| Q3 2024 | 2024-09-30 | −$68.6M | $53.0M | — | −49.19% |
| Q2 2024 | 2024-06-30 | −$79.0M | $51.1M | — | −53.71% |
| Q1 2024 | 2024-03-31 | −$193.9M | −$12.0M | — | −178.20% |
| Q4 2023 | 2023-12-31 | −$85.4M | $31.9M | — | −67.19% |
| Q3 2023 | 2023-09-30 | −$121.6M | −$178,000 | — | −123.98% |
| Q2 2023 | 2023-06-30 | −$130.1M | −$21.9M | — | −120.12% |
| Q1 2023 | 2023-03-31 | −$181.9M | −$32.2M | — | −181.00% |
| Q4 2022 | 2022-12-31 | −$117.3M | −$46.9M | — | −113.51% |
| Q3 2022 | 2022-09-30 | −$121.4M | −$41.2M | — | −133.83% |
| Q2 2022 | 2022-06-30 | −$108.2M | −$22.8M | — | −121.08% |
| Q1 2022 | 2022-03-31 | −$149.7M | $26.1M | — | −187.28% |
| Q4 2021 | 2021-12-31 | −$70.4M | $14.0M | — | −84.41% |
| Q3 2021 | 2021-09-30 | −$80.2M | −$14.5M | — | −98.24% |
| Q2 2021 | 2021-06-30 | −$85.4M | −$168.7M | — | −98.22% |
| Q1 2021 | 2021-03-31 | −$175.8M | −$66.5M | — | −176.83% |
| Q4 2020 | 2020-12-31 | −$84.4M | −$859,000 | — | −92.20% |
| Q3 2020 | 2020-09-30 | −$65.7M | $27.8M | — | −80.70% |
| Q2 2020 | 2020-06-30 | $83.3M | $177.6M | — | +134.94% |
| Q1 2020 | 2020-03-31 | −$109.2M | −$10.4M | — | −300.88% |
| Q4 2019 | 2019-12-31 | −$83.5M | −$26.5M | — | −234.71% |
| Q3 2019 | 2019-09-30 | −$93.5M | −$23.4M | — | −362.55% |
| Q2 2019 | 2019-06-30 | −$94.3M | −$16.8M | — | −390.50% |
| Q1 2019 | 2019-03-31 | −$98.8M | −$8.9M | — | −543.88% |
| Q4 2018 | 2018-12-31 | −$57.0M | $25.7M | — | −350.81% |
| Q3 2018 | 2018-09-30 | −$70.2M | −$7.2M | — | −596.69% |
| Q2 2018 | 2018-06-30 | −$77.5M | −$28.3M | — | −605.40% |
| Q1 2018 | 2018-03-31 | −$90.0M | −$28.3M | — | −842.49% |
| Q4 2017 | 2017-12-31 | −$82.7M | −$34.4M | — | −3426.76% |
| Q3 2017 | 2017-09-30 | −$63.0M | −$31.3M | — | −31831.31% |
| Q2 2017 | 2017-06-30 | −$49.2M | −$4.5M | — | — |
| Q1 2017 | 2017-03-31 | −$61.7M | −$15.3M | — | — |
| Q4 2016 | 2016-12-31 | −$48.3M | −$6.0M | — | −966920.00% |
| Q3 2016 | 2016-09-30 | −$31.7M | $833,000 | — | −28600.00% |
| Q2 2016 | 2016-06-30 | −$44.7M | −$26.8M | — | −262935.29% |
| Q1 2016 | 2016-03-31 | −$46.4M | −$28.3M | — | — |
| Q4 2015 | 2015-12-31 | −$42.4M | −$27.2M | — | — |
| Q3 2015 | 2015-09-30 | −$32.6M | −$21.1M | — | — |
| Q2 2015 | 2015-06-30 | −$17.9M | −$6.7M | — | — |
| Q1 2015 | 2015-03-31 | −$18.1M | −$9.2M | — | — |
| Q4 2014 | 2014-12-31 | −$15.2M | −$5.3M | — | — |
| Q3 2014 | 2014-09-30 | −$11.5M | −$4.5M | — | — |
| Q2 2014 | 2014-06-30 | −$11.2M | −$2.7M | — | — |
| Q1 2014 | 2014-03-31 | −$8.9M | −$2.4M | — | — |
| Q4 2013 | 2013-12-31 | −$9.9M | — | — | — |
| Q3 2013 | 2013-09-30 | −$7.0M | — | — | — |
| Q2 2013 | 2013-06-30 | −$8.5M | — | — | — |
| Q1 2013 | 2013-03-31 | −$6.5M | — | — | — |
Ultragenyx Pharmaceutical free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$176.1M to −$472.0M, a net decrease of $295.9M. Ultragenyx Pharmaceutical's latest reported quarter, Q2 2026, generated −$98.0M in free cash flow, an increase of $14.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Ultragenyx Pharmaceutical source filings ↗Community posts
Ultragenyx wins FDA approval for its Sanfilippo gene therapy
Ultragenyx ($RARE) received standard FDA approval for FAYUVI, the first approved treatment for Sanfilippo syndrome Type A. The single-infusion gene therapy treats neurological manifestations in pediatric patients with preserved neurodevelop ...
